

Optomed Q4 2022 - In line with our expectations

Redeye provides an update in relation to Optomed's Q4 2022 report. We argue the year has been in line with our expectations, with total sales of EUR14.7m (EUR14.9m), which can be compared to our sales estimate of EUR14.5m. We are positive the sales were at the same level as in 2021 due to the uncertainties in China, which has clearly affected the company. We have chosen not to make any changes in our estimates for the following years and look forward to the potential US launch during 2023. We reiterate our base case of EUR8.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Optomed Q4 2022 - In line with our expectations